COMMUNIQUÉS West-GlobeNewswire

Prima BioMed Changes Its Name to Immutep Ltd
20/11/2017
SYDNEY, Australia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep Ltd (“Immutep”) [...]
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
20/11/2017
Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory milestones, including addition [...]
MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain
20/11/2017
Promising market with an estimate of over 300.000 Spanish men with elevated PSA levels MDxHealth's urine test a non-invasive, molecular test clearly showing who could safely forego a painful biopsy, saving patients from [...]
MDxhealth fait équipe avec la société pharmaceutique Ferrer pour distribuer SelectMDx en Espagne
20/11/2017
Marché prometteur avec un nombre estimé de 300.000 hommes espagnols avec un taux de PSA élevé Le test urinaire moléculaire non-invasif de MDxHealth démontre clairement qui peut renoncer à une biopsie douloureuse en [...]
ALBATROSS with GLPG2222 shows positive clinical results in CF patients
19/11/2017
Evaluation of C1 corrector GLPG2222 on top of ivacaftor (Kalydeco ®[1] ) in heterozygous Class III/F508del CFTR patients Patient study recruited within 5 months in Europe and Australia GLPG2222 was well tolerated dosed [...]
Veritas Pharma Enters Binding Letter of Intent to Secure ACMPR License and Cannabis Growing Facility
18/11/2017
VANCOUVER, British Columbia, Nov. 18, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), ( “Veritas” or the “Company” ), an emerging-stage pharmaceutical and IP development company, is [...]
Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal
17/11/2017
Delisting notice was expected as part of the compliance extension previously granted by Nasdaq Continue “ANTH” listing until formal hearing process is complete with the Nasdaq Hearings Panel HAYWARD, Calif., Nov. 17, [...]
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
17/11/2017
Valby, Denmark, 2017-11-17 18:55 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 17 November 2017 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with [...]
CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research
17/11/2017
SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]
Doctors Manitoba selects Theresa Oswald as new CEO
17/11/2017
WINNIPEG, Manitoba, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Doctors Manitoba has selected Theresa Oswald as its new Chief Executive Officer starting in January 2018. Well known to the medical community around the country as [...]
American Health Council Recognizes Anikar Chhabra, MD, MS as “America’s Best Doctor”
17/11/2017
NEW YORK, Nov. 17, 2017 (GLOBE NEWSWIRE) -- The American Health Council names Anikar Chhabra as “America’s Best Doctor” for a dynamic medical career marked by compassionate patient care. Presently an Associate Professor [...]
MRI Interventions to Present at LD Micro Main Event Conference on December 6
17/11/2017
IRVINE, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), today announced that Joe Burnett, CEO, will present at the 10 th Annual LD Micro Main Event Conference on Wednesday, December 6, [...]
Flexion Therapeutics Named Top Place to Work for 2017 by The Boston Globe
17/11/2017
Annual survey recognizes and honors the best employers in Massachusetts BURLINGTON, Mass., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that it has been named one of the [...]
VBL Therapeutics Prices 2.5 Million Ordinary Share Offering
17/11/2017
TEL AVIV, Israel, Nov. 17, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]
Helius Medical Technologies Provides Clarification on Clinical Trial Results and Confirms Intention to Include Traumatic Brain Injury (TBI) Registrational and Long-Term Treatment Trial Data to Support Application for Clearance by the FDA
17/11/2017
NEWTOWN, Pa., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX: HSM ) (OTCQB:HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellness, has received [...]
ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference
17/11/2017
MOUNTAIN VIEW, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI ), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today [...]
Vilacto Bio Inc. Retains Established Independent Investor Relations Firm, The Equity Group Inc.
17/11/2017
COPENHAGEN, Denmark, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTCQB:VIBI), today announced that it has retained The Equity Group Inc. to facilitate all aspects of the Company’s investor relations and [...]
International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017
17/11/2017
CARLSBAD, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ( www.internationalstemcell.com ) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company [...]
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
17/11/2017
HAMPTON, N.J., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq: CLDX ) announced today that enrollment has opened in its open-label Phase 2 study of CDX-3379 in combination with cetuximab in [...]

Pages